155 related articles for article (PubMed ID: 34364187)
21. Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study.
Moschini M; Fossati N; Sood A; Lee JK; Sammon J; Sun M; Pucheril D; Dalela D; Montorsi F; Karnes RJ; Briganti A; Trinh QD; Menon M; Abdollah F
Eur Urol Focus; 2018 Jan; 4(1):68-74. PubMed ID: 28753764
[TBL] [Abstract][Full Text] [Related]
22. Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients.
Suardi N; Gallina A; Capitanio U; Salonia A; Lughezzani G; Freschi M; Mottrie A; Rigatti P; Montorsi F; Briganti A
Cancer; 2012 Feb; 118(4):973-80. PubMed ID: 21751185
[TBL] [Abstract][Full Text] [Related]
23. Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9-10 at biopsy: A population-based analysis.
Knipper S; Palumbo C; Pecoraro A; Rosiello G; Tian Z; Briganti A; Zorn KC; Saad F; Tilki D; Graefen M; Karakiewicz PI
Urol Oncol; 2020 Mar; 38(3):79.e9-79.e14. PubMed ID: 31653563
[TBL] [Abstract][Full Text] [Related]
24. Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy.
Beauval JB; Ploussard G; Cabarrou B; Roumiguié M; Ouzzane A; Gas J; Goujon A; Marcq G; Mathieu R; Vincendeau S; Cathelineau X; Mongiat-Artus P; Salomon L; Soulié M; Méjean A; de La Taille A; Rouprêt M; Rozet F;
World J Urol; 2017 Aug; 35(8):1191-1197. PubMed ID: 27987030
[TBL] [Abstract][Full Text] [Related]
25. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
[TBL] [Abstract][Full Text] [Related]
26. Tumor upgrading among very favorable intermediate-risk prostate cancer patients treated with robot-assisted radical prostatectomy: how can it impact the clinical course?
Porcaro AB; Bianchi A; Panunzio A; Gallina S; Serafin E; Tafuri A; Trabacchin N; Orlando R; Ornaghi PI; Mazzucato G; Vidiri S; D'Aietti D; Montanaro F; Brusa D; Patuzzo GM; Artoni F; Baielli A; Migliorini F; De Marco V; Veccia A; Brunelli M; Siracusano S; Cerruto MA; Antonelli A
Int Urol Nephrol; 2024 Mar; ():. PubMed ID: 38553619
[TBL] [Abstract][Full Text] [Related]
27. The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients.
Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Shariat SF; Saad F; Montorsi F; Briganti A; Karakiewicz PI
Urol Oncol; 2021 Nov; 39(11):785.e11-785.e17. PubMed ID: 33992522
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.
Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
Int J Clin Oncol; 2015 Feb; 20(1):176-81. PubMed ID: 24771079
[TBL] [Abstract][Full Text] [Related]
29. Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates selection.
Gandaglia G; Schiffmann J; Schlomm T; Fossati N; Moschini M; Suardi N; Chun FK; Montorsi F; Graefen M; Briganti A
Prostate; 2015 Sep; 75(13):1484-91. PubMed ID: 26177942
[TBL] [Abstract][Full Text] [Related]
30. Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review.
Kane CJ; Eggener SE; Shindel AW; Andriole GL
Eur Urol Focus; 2017 Oct; 3(4-5):487-497. PubMed ID: 28753804
[TBL] [Abstract][Full Text] [Related]
31. A solitary positive prostate cancer biopsy does not predict a unilateral lesion in radical prostatectomy specimens.
Koie T; Mitsuzuka K; Narita S; Yoneyama T; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C
Scand J Urol; 2015 Apr; 49(2):103-7. PubMed ID: 25165894
[TBL] [Abstract][Full Text] [Related]
32. External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients.
Beauval JB; Cabarrou B; Gandaglia G; Patard PM; Ouzzane A; de la Taille A; Soulié M; Briganti A; Ploussard G; Rozet F; Roumiguié M
Prostate; 2017 Jun; 77(8):928-933. PubMed ID: 28370267
[TBL] [Abstract][Full Text] [Related]
33. Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment.
Pompe RS; Davis-Bondarenko H; Zaffuto E; Tian Z; Shariat SF; Leyh-Bannurah SR; Schiffmann J; Saad F; Huland H; Graefen M; Tilki D; Karakiewicz PI
Prostate; 2017 May; 77(6):686-693. PubMed ID: 28156003
[TBL] [Abstract][Full Text] [Related]
34. Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy.
Yashi M; Nukui A; Tokura Y; Takei K; Suzuki I; Sakamoto K; Yuki H; Kambara T; Betsunoh H; Abe H; Fukabori Y; Nakazato Y; Kaji Y; Kamai T
BMC Urol; 2017 Jun; 17(1):47. PubMed ID: 28645325
[TBL] [Abstract][Full Text] [Related]
35. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.
Zelefsky MJ; Eastham JA; Cronin AM; Fuks Z; Zhang Z; Yamada Y; Vickers A; Scardino PT
J Clin Oncol; 2010 Mar; 28(9):1508-13. PubMed ID: 20159826
[TBL] [Abstract][Full Text] [Related]
36. Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables.
Würnschimmel C; Nocera L; Wenzel M; Ruvolo CC; Tian Z; Saad F; Briganti A; Shariat SF; Mirone V; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
J Racial Ethn Health Disparities; 2023 Apr; 10(2):708-717. PubMed ID: 35182370
[TBL] [Abstract][Full Text] [Related]
37. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer.
Briganti A; Joniau S; Gontero P; Abdollah F; Passoni NM; Tombal B; Marchioro G; Kneitz B; Walz J; Frohneberg D; Bangma CH; Graefen M; Tizzani A; Frea B; Karnes RJ; Montorsi F; Van Poppel H; Spahn M
Eur Urol; 2012 Mar; 61(3):584-92. PubMed ID: 22153925
[TBL] [Abstract][Full Text] [Related]
38. Is supplemental external beam radiation therapy essential to maximize brachytherapy outcomes in patients with unfavorable intermediate-risk disease?
Merrick GS; Wallner KE; Galbreath RW; Butler WM; Adamovich E
Brachytherapy; 2016; 15(1):79-84. PubMed ID: 26525214
[TBL] [Abstract][Full Text] [Related]
39. Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer.
Muralidhar V; Catalano PJ; Reznor G; Mahal BA; Choueiri TK; Sweeney CJ; Martin NE; Beard CJ; Chen YW; Nezolosky MD; Hoffman KE; Feng FY; Trinh QD; Nguyen PL
J Natl Compr Canc Netw; 2016 Apr; 14(4):421-8. PubMed ID: 27059190
[TBL] [Abstract][Full Text] [Related]
40. Tumor characteristics, treatments, and survival outcomes in prostate cancer patients with a PSA level < 4 ng/ml: a population-based study.
Zheng Z; Zhou Z; Yan W; Zhou Y; Chen C; Li H; Ji Z
BMC Cancer; 2020 Apr; 20(1):340. PubMed ID: 32321456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
